Hiroomi Tada
2022
In 2022, Hiroomi Tada earned a total compensation of $1.3M as Chief Medical Officer at Tyra Biosciences, a 50% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $215,600 |
|---|---|
| Option Awards | $563,937 |
| Salary | $486,250 |
| Other | $950 |
| Total | $1,266,737 |
Tada received $563.9K in option awards, accounting for 45% of the total pay in 2022.
Tada also received $215.6K in non-equity incentive plan, $486.3K in salary and $950 in other compensation.
Rankings
In 2022, Hiroomi Tada's compensation ranked 2,570th out of 5,736 executives tracked by ExecPay. In other words, Tada earned more than 55.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,570 out of 5,736 | 55th |
Division Manufacturing | 1,425 out of 3,125 | 54th |
Major group Chemicals And Allied Products | 648 out of 1,416 | 54th |
Industry group Drugs | 602 out of 1,317 | 54th |
Industry Pharmaceutical Preparations | 432 out of 963 | 55th |
Source: SEC filing on April 18, 2024.
Tada's colleagues
We found three more compensation records of executives who worked with Hiroomi Tada at Tyra Biosciences in 2022.